MA52400B1 - Composition de vaccin combinée pour administration multiple - Google Patents

Composition de vaccin combinée pour administration multiple

Info

Publication number
MA52400B1
MA52400B1 MA52400A MA52400A MA52400B1 MA 52400 B1 MA52400 B1 MA 52400B1 MA 52400 A MA52400 A MA 52400A MA 52400 A MA52400 A MA 52400A MA 52400 B1 MA52400 B1 MA 52400B1
Authority
MA
Morocco
Prior art keywords
vaccine
composition
combination
present
combination vaccine
Prior art date
Application number
MA52400A
Other languages
English (en)
Other versions
MA52400A1 (fr
Inventor
Suk Young Choi
Yoon Ae Noh
Eun Ji Kim
Original Assignee
Lg Chemical Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lg Chemical Ltd filed Critical Lg Chemical Ltd
Publication of MA52400A1 publication Critical patent/MA52400A1/fr
Publication of MA52400B1 publication Critical patent/MA52400B1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A61K33/08—Oxides; Hydroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/11—Aldehydes
    • A61K31/115—Formaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0017—Combination vaccines based on whole cell diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0016—Combination vaccines based on diphtheria-tetanus-pertussis
    • A61K39/0018—Combination vaccines based on acellular diphtheria-tetanus-pertussis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/102—Pasteurellales, e.g. Actinobacillus, Pasteurella; Haemophilus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2730/00—Reverse transcribing DNA viruses
    • C12N2730/00011—Details
    • C12N2730/10011—Hepadnaviridae
    • C12N2730/10111—Orthohepadnavirus, e.g. hepatitis B virus
    • C12N2730/10134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32611—Poliovirus
    • C12N2770/32634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Inorganic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)

Abstract

La présente invention concerne une composition immunogène à doses multiples pour un vaccin combiné multivalent, dans laquelle (i) le vaccin combiné multivalent contient un vaccin contre la coqueluche vaccin à cellules entières (wp) ou un vaccin contre la coqueluche acellulaire(ap), et un vaccin contre la polio inactivé sabin (sipv) ; et (ii) la composition contient du 2-phénoxyéthanol (2-pe) et du formaldéhyde (hcho) en tant que conservateurs ; et un procédé de préparation d’une composition immunogène à doses multiples pour un vaccin combiné multivalent. Il a été confirmé que la combinaison de 2-phénoxyéthanol et de formaldéhyde selon la présente invention est un excellent conservateur capable de maintenir une capacité antimicrobienne et qu’elle peut être efficacement utilisée pour produire une composition à doses multiples, maintenir la capacité antimicrobienne d’un vaccin combiné, ce de sorte que la composition de la présente invention puisse être efficacement utilisée dans l’industrie des vaccins combinés à doses multiples.
MA52400A 2015-09-16 2016-09-13 Composition de vaccin combinée pour administration multiple MA52400B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR20150131157 2015-09-16
PCT/KR2016/010313 WO2017048038A1 (fr) 2015-09-16 2016-09-13 Composition de vaccin combinée pour administration multiple

Publications (2)

Publication Number Publication Date
MA52400A1 MA52400A1 (fr) 2022-06-30
MA52400B1 true MA52400B1 (fr) 2023-01-31

Family

ID=58289554

Family Applications (2)

Application Number Title Priority Date Filing Date
MA42317A MA42317B2 (fr) 2015-09-16 2016-09-13 Composition de vaccin combinée pour administration multiple
MA52400A MA52400B1 (fr) 2015-09-16 2016-09-13 Composition de vaccin combinée pour administration multiple

Family Applications Before (1)

Application Number Title Priority Date Filing Date
MA42317A MA42317B2 (fr) 2015-09-16 2016-09-13 Composition de vaccin combinée pour administration multiple

Country Status (7)

Country Link
KR (1) KR101864029B1 (fr)
BR (1) BR112018005291A2 (fr)
EA (1) EA037283B1 (fr)
MA (2) MA42317B2 (fr)
PH (1) PH12018500570A1 (fr)
TN (1) TN2018000063A1 (fr)
WO (1) WO2017048038A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2018169303A1 (fr) * 2017-03-15 2018-09-20 주식회사 엘지화학 Composition vaccinale polyvalente contre streptococcus pneumoniae
BR112020000999A2 (pt) * 2017-07-18 2020-07-14 Serum Institute Of India Pvt Ltd. composição imunogênica tendo estabilidade aperfeiçoada, imunogenicidade melhorada e reatogenicidade reduzida e processo para a sua preparação
CA3115803A1 (fr) * 2018-10-12 2020-04-16 Serum Institute Of India Private Ltd. Composition vaccinale combinee comprenant un poliovirus inactive a dose reduite et son procede de preparation
WO2021176409A1 (fr) 2020-03-05 2021-09-10 Sanofi Healthcare India Private Limited Combinaison de conservateurs pour composition de vaccin

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR920009729B1 (ko) * 1990-08-29 1992-10-22 주식회사 녹십자 백일해, 디프테리아, 파상풍 및 b형 간염의 동시 예방을 위한 혼합백신
KR920009729A (ko) * 1990-11-26 1992-06-25 전금자 원적외선이 발생하는 도자기 제조방법
DE69319728T2 (de) * 1992-05-23 1999-02-04 Smithkline Beecham Biologicals S.A., Rixensart Kombinierte Impfstoffe, die Hepatitis B oberfläche Antigen und andere Antigenen enthalten
EP2505192B1 (fr) * 2007-09-12 2016-05-04 Galderma Research & Development Utilisation d'excipients en tant que conservateurs et composition pharmaceutique les comprenant
PE20100365A1 (es) * 2008-10-24 2010-05-21 Panacea Biotec Ltd Novedosas vacunas de combinacion con tos ferina de celulas enteras y metodo para su elaboracion
US20140112950A1 (en) * 2011-03-02 2014-04-24 Manmohan Singh Combination vaccines with lower doses of antigen and/or adjuvant

Also Published As

Publication number Publication date
KR101864029B1 (ko) 2018-06-01
WO2017048038A1 (fr) 2017-03-23
MA52400A1 (fr) 2022-06-30
KR20170033254A (ko) 2017-03-24
PH12018500570A1 (en) 2018-09-17
EA037283B1 (ru) 2021-03-04
EA201890502A1 (ru) 2018-08-31
TN2018000063A1 (en) 2019-07-08
BR112018005291A2 (pt) 2018-10-09
MA42317B2 (fr) 2021-11-30

Similar Documents

Publication Publication Date Title
MX2023009011A (es) Inhibidor de cdk.
MA52400A1 (fr) Composition de vaccin combinée pour administration multiple
CY1121418T1 (el) Παρεμποδιστες ιου ηπατιτιδας c
GT201500021A (es) Sulfamoilarilamidas y su uso como medicamentos para el tratamiento de la hepatitis b
MX2019005379A (es) Derivado de pirazolo-heteroarilo, metodo de preparacion y uso medico del mismo.
CL2017002230A1 (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor del ensamblaje de la cápsida del vhb.
AR101674A1 (es) Uso de un compuesto tricíclico que contiene nitrógeno
EP4592275A3 (fr) Composés hydrazinyl-pyrrolo et procédés de production d'un conjugué
BR112016008468A2 (pt) Composto de fórmula, composição farmacêutica, composto, uso de um composto e método para o tratamento ou melhora de câncer
MX388408B (es) Tratamiento combinado con un agonista de tlr7 y un inhibidor de montaje de capsida de hbv
EA202090098A1 (ru) Фармацевтические композиции терапевтически активных соединений
CA3030422C (fr) Excipients stabilisants pour formulations de proteines therapeutiques
BR112015008417A2 (pt) composição imunogênica, e, vacina
AR108889A1 (es) Combinaciones para el tratamiento del cáncer
PH12017501370A1 (en) Bivalent swine influenza virus vaccine
ECSP16084317A (es) Formulaciones farmacéuticas, procesos para la preparación y métodos de uso
MX384875B (es) Método para obtener una vacuna de mycoplasma.
MX381617B (es) Conjugados de peptido-curcumina y formulaciones de los mismos.
IN2013MU00711A (fr)
AR112405A1 (es) Tratamiento de cáncer de mama triple negativo o cáncer colorrectal con metástasis hepáticas
PE20211648A1 (es) Composicion de vacuna combinada que comprende dosis reducidas del virus inactivado de la polio y metodo de preparacion de la misma
CO6430435A2 (es) Nuevas vacunas combinadas con células completas de pertussis y método de fabricación de las mismas
MX2016014740A (es) Un metodo para el tratamiento de trastornos del movimiento con befiradol.
MX2021012201A (es) Adyuvante soluble en agua.
MX2022006054A (es) Dosificacion y administracion de una vacuna de glucoconjugados de sacaridos bacterianos.